Cargando…
Pulmonary surfactant itself must be a strong defender against SARS-CoV-2
Pulmonary surfactant is considered to be one of the soaps. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the other enveloped viruses become very weak against surfactant. The SARS virus binds to angiotensin-converting enzyme (ACE2) receptor and causes pneumonia. In the lung, the AC...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833517/ https://www.ncbi.nlm.nih.gov/pubmed/32590326 http://dx.doi.org/10.1016/j.mehy.2020.110020 |
_version_ | 1783642083538501632 |
---|---|
author | Takano, Hideyuki |
author_facet | Takano, Hideyuki |
author_sort | Takano, Hideyuki |
collection | PubMed |
description | Pulmonary surfactant is considered to be one of the soaps. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the other enveloped viruses become very weak against surfactant. The SARS virus binds to angiotensin-converting enzyme (ACE2) receptor and causes pneumonia. In the lung, the ACE2 receptor sits on the top of lung cells known as alveolar epithelial type II (AE2) cells. These cells play an important role in producing surfactant. Pulmonary surfactant is believed to regulate the alveolar surface tension in mammalian lungs. To our knowledge, AE2 cells are believed to act as immunoregulatory cells; however, pulmonary surfactant itself has not been believed to act as a defender against the enveloped viruses. This study hypothesises that pulmonary surfactant may be a strong defender of enveloped viruses. Therefore, old coronaviruses merely cause pneumonia. On the contrary, new SARS-CoV-2 can suppress the production of surfactant that binds to the ACE2 of AE2 cells. The coronavirus can survive in the lung tissue because of the exhaustion of pulmonary surfactant. |
format | Online Article Text |
id | pubmed-7833517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78335172021-01-26 Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 Takano, Hideyuki Med Hypotheses Article Pulmonary surfactant is considered to be one of the soaps. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the other enveloped viruses become very weak against surfactant. The SARS virus binds to angiotensin-converting enzyme (ACE2) receptor and causes pneumonia. In the lung, the ACE2 receptor sits on the top of lung cells known as alveolar epithelial type II (AE2) cells. These cells play an important role in producing surfactant. Pulmonary surfactant is believed to regulate the alveolar surface tension in mammalian lungs. To our knowledge, AE2 cells are believed to act as immunoregulatory cells; however, pulmonary surfactant itself has not been believed to act as a defender against the enveloped viruses. This study hypothesises that pulmonary surfactant may be a strong defender of enveloped viruses. Therefore, old coronaviruses merely cause pneumonia. On the contrary, new SARS-CoV-2 can suppress the production of surfactant that binds to the ACE2 of AE2 cells. The coronavirus can survive in the lung tissue because of the exhaustion of pulmonary surfactant. Elsevier Ltd. 2020-11 2020-06-20 /pmc/articles/PMC7833517/ /pubmed/32590326 http://dx.doi.org/10.1016/j.mehy.2020.110020 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Takano, Hideyuki Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 |
title | Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 |
title_full | Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 |
title_fullStr | Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 |
title_full_unstemmed | Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 |
title_short | Pulmonary surfactant itself must be a strong defender against SARS-CoV-2 |
title_sort | pulmonary surfactant itself must be a strong defender against sars-cov-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833517/ https://www.ncbi.nlm.nih.gov/pubmed/32590326 http://dx.doi.org/10.1016/j.mehy.2020.110020 |
work_keys_str_mv | AT takanohideyuki pulmonarysurfactantitselfmustbeastrongdefenderagainstsarscov2 |